Recurrent Glioblastoma Multiforme Clinical Trial
Official title:
Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
This is a multi-center, phase Ib/ II study (two parts) with patients that had recurrent glioblastoma multiforme. The first part (phase Ib) was to investigate the maximum tolerated dose/Recommended phase ll dose (MTD/RP2D) of once daily buparlisib in combination with every-three-week carboplatin or buparlisib once daily in combination with every-six-week lomustine (CCNU) using a Bayesian model. Once MTD/ RP2D is established in either of the 2 arms, the corresponding phase II portion of the study was to start. Phase II was to assess the treatment effect of buparlisib in combination with carboplatin in terms of Progression Free Survival (PFS) and was to compare the treatment effect of buparlisib with lomustine versus lomustine plus placebo in terms of PFS. A preliminary assessment for both combinations (buparlisib plus carboplatin or lomustine) demonstrated that there was not enough antitumor activity compared to historical data with single agent carboplatin or lomustine. Based on the overall safety profile, and preliminary anti-tumor activity observed in this study, Novartis decided that no additional patients would be enrolled into this study. As a consequence, the Phase II part of the study was not conducted.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00597493 -
Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM
|
Phase 2 | |
| Completed |
NCT00379470 -
Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)
|
Phase 3 | |
| Recruiting |
NCT01737346 -
Procarbazine and Lomustine in Recurrent Glioblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT01464177 -
Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme
|
Phase 2 | |
| Active, not recruiting |
NCT00562419 -
CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan
|
Phase 2 | |
| Completed |
NCT00071539 -
Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT02062827 -
Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
|
Phase 1 | |
| Completed |
NCT00509301 -
Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme
|
Phase 1 | |
| Recruiting |
NCT05868083 -
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma
|
Phase 1 | |
| Completed |
NCT01576666 -
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01738646 -
Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients
|
Phase 2 | |
| Completed |
NCT00306618 -
Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma
|
Phase 2 | |
| Recruiting |
NCT04915404 -
Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)
|
Phase 1/Phase 2 | |
| Terminated |
NCT01756729 -
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
|
Phase 4 | |
| Completed |
NCT00747253 -
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
|
Phase 1 | |
| Completed |
NCT00883298 -
Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
| Completed |
NCT00481455 -
Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)
|
Phase 2 | |
| Recruiting |
NCT03423628 -
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
|
Phase 1 | |
| Recruiting |
NCT04689087 -
A Prospective, Open-label, Single-arm Clinical Study
|
N/A |